This post is from a suggested group
The ONE Reason Why This Market is Booming!
The rising global cancer burden is a primary driver of the PD-1 and PD-L1 inhibitor market. The World Health Organization (WHO) projects a significant increase in new cancer cases, which is anticipated to drive demand for effective cancer treatments like PD-1 and PD-L1 inhibitors.
As the number of cancer cases increases, the demand for advanced, targeted therapies that offer better efficacy and improved side effect profiles is also rising, propelling the market forward.